Are you preparing to move from preclinical development into first-in-human studies?
The transition into clinical development is a critical stage for any drug development programme. Early decisions around regulatory strategy, clinical planning, study design and evidence generation can have a significant impact on timelines, risk and future development success.
In this live ‘Ask the Experts’ Q&A, our experts, Dr Jon Sisson and Christopher Floyd, explored:
○ Key considerations before moving into first-in-human studies
○ How early planning can help avoid avoidable delays
○ Where regulatory, clinical and development strategy should align
Get practical insights to help you strengthen decision-making, reduce programme risk and move towards first-in-human studies with greater confidence. Download to watch the recording by filling up the contact form.
Need Support?
tranScrip’s experts support biotech and pharma companies across early development, regulatory strategy, clinical planning and first-in-human readiness. For bespoke support with your development programme, connect with us today > Contact us.
